Cargando…
Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial
AIMS: Sodium‐glucose cotransporter‐2 inhibitors induce less weight loss than expected. This may be explained by sodium‐glucose cotransporter‐2 inhibitor‐induced alterations in central reward‐ and satiety circuits, leading to increased appetite and food intake. Glucagon‐like peptide‐1 receptor agonis...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Blackwell Publishing Ltd
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546212/ https://www.ncbi.nlm.nih.gov/pubmed/35491524 http://dx.doi.org/10.1111/dom.14732 |